- Home
- MSSA vs ONCY Comparison
MSSA vs ONCY Comparison
Compare MSSA & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSSA
- ONCY
- Stock Information
- Founded
- MSSA 2021
- ONCY 1998
- Country
- MSSA United States
- ONCY Canada
- Employees
- MSSA N/A
- ONCY N/A
- Industry
- MSSA
- ONCY Pharmaceuticals and Biotechnology
- Sector
- MSSA
- ONCY Health Care
- Exchange
- MSSA NYSE
- ONCY Nasdaq
- Market Cap
- MSSA 74.6M
- ONCY 86.1M
- IPO Year
- MSSA 2022
- ONCY 1999
- Fundamental
- Price
- MSSA $12.00
- ONCY $0.98
- Analyst Decision
- MSSA
- ONCY Strong Buy
- Analyst Count
- MSSA 0
- ONCY 2
- Target Price
- MSSA N/A
- ONCY $4.00
- AVG Volume (30 Days)
- MSSA 1.8K
- ONCY 386.7K
- Earning Date
- MSSA 01-01-0001
- ONCY 11-12-2024
- Dividend Yield
- MSSA N/A
- ONCY N/A
- EPS Growth
- MSSA N/A
- ONCY N/A
- EPS
- MSSA 0.20
- ONCY N/A
- Revenue
- MSSA N/A
- ONCY N/A
- Revenue This Year
- MSSA N/A
- ONCY N/A
- Revenue Next Year
- MSSA N/A
- ONCY N/A
- P/E Ratio
- MSSA $60.97
- ONCY N/A
- Revenue Growth
- MSSA N/A
- ONCY N/A
- 52 Week Low
- MSSA $10.89
- ONCY $0.84
- 52 Week High
- MSSA $12.00
- ONCY $1.75
- Technical
- Relative Strength Index (RSI)
- MSSA 82.76
- ONCY 36.89
- Support Level
- MSSA $11.60
- ONCY $1.01
- Resistance Level
- MSSA $11.68
- ONCY $1.15
- Average True Range (ATR)
- MSSA 0.02
- ONCY 0.06
- MACD
- MSSA 0.01
- ONCY -0.03
- Stochastic Oscillator
- MSSA 100.00
- ONCY 3.14
About MSSA METAL SKY STAR ACQUISITION CORP
Metal Sky Star Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.